Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 9/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | TNKS | O95271 | 7/20 | 0.63 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.63 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.63 |
| ▸ | PARP1 | P09874 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28646510 | 0.86 | TNKS (0.67) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL17816407 | 0.84 | TNKS (0.63) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL14159934 | 0.83 | NPC1 (0.49) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL4712542 | 0.83 | PTGES (0.53) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL3110381 | 0.83 | TNKS (0.62) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL6695759 | 0.82 | TNKS2 (0.81) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL28135155 | 0.82 | GUSB (0.69) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL802560 | 0.81 | GUSB (0.68) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL2606253 | 0.81 | GUSB (0.68) | GUSBHPGDKDM4ETNKSTNKS2 | |
| SCHEMBL29784109 | 0.81 | GUSB (0.68) | GUSBHPGDKDM4ETNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518789-B | A method of synthesis Quinazol derivative | 南京理工大学 | 2019-04-16 | — | — | CN | disclosed |
| CN-106518789-A | Method for synthesis of quinazolinone derivative | 南京理工大学 | 2017-03-22 | — | — | CN | disclosed |
| CN-106496146-A | Catalytic regulation synthesis method of sulfonic acid ionic liquid of dihydro quinazolinone and quinazolinone derivative | 江西师范大学 | 2017-03-15 | — | — | CN | disclosed |
| CN-106478525-A | A kind of method of synthesis quinazolone | 南京理工大学 | 2017-03-08 | — | — | CN | disclosed |
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268857-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1603908-B1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | MILLENNIUM PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189733-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1603908-A1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040204431-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004081009-A1 | QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| US-5849861-A | Polyquinazolines and methods for their preparation | HITACHI CHEMICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| US-5686560-A | TREATING A MONOMER WITH A BASE IN A DIPOLAR SOLVENT | HITACHI CHEMICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204431-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFBR2, TGFB2 | GUSB 800/4885HPGD 3156/4885KDM4E 1309/4885 |
| US-20070142408-A1 | Compositions and methods for inhibiting TGF-Beta | TGFB1, TGFB2, TGFBR1 | GUSB 539/4885HPGD 2485/4885KDM4E 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.